anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Stroke-heart syndrome (SHS), a critical yet underrecognized condition, encompasses a range of cardiac complications that arise following an ischemic stroke. This narrative review explores the pathophysiology, clinical manifestations, and implications of SHS, focusing on the complex interplay between the brain and the heart. Acute ischemic stroke (AIS) triggers autonomic dysfunction, leading to a surge in catecholamines and subsequent myocardial injury. Our review highlights the five cardinal manifestations of SHS: elevated cardiac troponin (cTn) levels, acute myocardial infarction, left ventricular dysfunction, arrhythmias, and sudden cardiac death. Despite the significant impact of these complications on patient outcomes, there is a notable absence of specific guidelines for their management. Through a comprehensive literature search, we synthesized findings from recent studies to elucidate the mechanisms underlying SHS and identified gaps in the current understanding. Our findings underscore the importance of early detection and multidisciplinary management of cardiac complications post-stroke. Future research should focus on establishing evidence-based protocols to improve clinical outcomes for stroke patients with SHS. Addressing this unmet need will enhance the care of stroke survivors and reduce mortality rates associated with cardiac complications.
Improved cyclodextrin formulations for the administration of 5 .beta. steroids including a etiocholanolone, .beta. etiocholonolone, and etiocholandione are provided. Also provided are cyclodextrin formulations including at least one of the 5 .beta. steroids and DHEA. The formulations are suitable for parenteral administration, particularly intravenous administration and are also suitable for treating a condition which responds to treatment with the 5 .beta. steroids alone or together with DHEA, particularly where it is desired to decrease the amount of DHEA administered, including such conditions as obesity, diabetes syndrome, diabetes-associated hypercorticoidism or combinations thereof, anemic disorders including but not limited to aplastic anemia and anemia associated with renal failure or chemotherapy-induced or radiation-induced anemia or neutropenia, and autoimmune or inflammatory disorders such as lupus erythematosus.
Eligible subjects will receive up to 4 cycles of combined modality treatment. The number of cycles depends on response, toxicity, and the remaining cell dose.
Diabetic patients will use Standard Blood Glucose Monitoring (SMBG) to monitor glucose level for 3 months. A 14-day masked wear of FreeStyle Libre H Flash Glucose Monitoring system is included for these subjects once a month, to collect glycaemic variability data for comparison to the intervention group of the study.
Including a German sleep committee a new questionnaire has been created to ask patients about their travel Habits. Only travels over a onenightstay were of interest. All detailed Information about the Destination has been asked. A Special Point of interest were the Impacts of traveling. For each Patient a doctor completed the medical history including sleep related breathing disorder and relevant medical conditions e.g. orthopedic Impacts.
The present invention discloses a medical image project management platform comprising a project management module and a radiomics extracting module. The project management module comprises a multi-module management interface and a labelling unit. An image is input by the multi-module management interface and received by the labelling unit so that a first labelled image and a second labelled image of the image are produced. The radiomics extracting module comprises an analysis unit and a radiomic extracting unit. The analysis unit analyzes the first labelled image and gives the first labelled image a first labelling unit. The analysis unit analyzes the second labelled image and gives the second labelled image a second labelling unit. The radiomics extracting unit receives the first labelling unit and the second labelling unit and proceeds radiomic computation so as to output a radiomics.
BECAUSE OF THE POSSIBILITY OF SEVERE TOXIC REACTIONS, ALL PATIENTS SHOULD BE HOSPITALIZED FOR THE FIRST COURSE OF THERAPY.

Floxuridine should be used with extreme caution in poor risk patients with impaired hepatic or renal function or a history of high-dose pelvic irradiation or previous use of alkylating agents. The drug is not intended as an adjuvant to surgery.

Floxuridine may cause fetal harm when administered to a pregnant woman. It has been shown to be teratogenic in the chick embryo, mouse (at doses of 2.5 to 100 mg/kg) and rat (at doses of 75 to 150 mg/kg). Malformations included cleft palates; skeletal defects; and deformed appendages, paws and tails. The dosages which were teratogenic in animals are 4.2 to 125 times the recommended human therapeutic dose.

There are no adequate and well-controlled studies with floxuridine in pregnant women. If this drug is used during pregnancy or if the patient becomes pregnant while taking (receiving) this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.
Elderly patients, compared to younger patients, are at greater risk for NSAID-associated serious cardiovascular, gastrointestinal, and/or renal adverse reactions. If the anticipated benefit for the elderly patient outweighs these potential risks, start dosing at the low end of the dosing range, and monitor patients for adverse effects [see Warnings and Precautions (5.1, 5.2, 5.3, 5.6, 5.14)] . 

Of the total number of patients who received naproxen and esomeprazole magnesium delayed-release tablets (n=1157) in clinical trials, 387 were ≥ 65 years of age, of which 85 patients were 75 years and over. No meaningful differences in efficacy or safety were observed between these subjects and younger subjects [see Adverse Reactions (6)]. 

Studies indicate that although total plasma concentration of naproxen is unchanged, the unbound plasma fraction of naproxen is increased in the elderly. Caution is advised when high doses are required and some adjustment of dosage may be required in elderly patients. As with other drugs used in the elderly, it is prudent to use the lowest effective dose [see Dosage and Administration (2), Clinical Pharmacology (12.3)]. 

Experience indicates that geriatric patients may be particularly sensitive to certain adverse effects of NSAIDs. Elderly or debilitated patients seem to tolerate peptic ulceration or bleeding less well when these events do occur. Most spontaneous reports of fatal GI events are in the geriatric population [see Warnings and Precautions (5.2)]. 

Naproxen and its metabolites are known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Geriatric patients may be at a greater risk for the development of a form of renal toxicity precipitated by reduced prostaglandin formation during administration of NSAIDs [see Warnings and Precautions (5.6)] .
Patients receive decitabine/cedazuridine PO daily on days 1-5, venetoclax PO daily on days 1-14, and ivosidenib PO daily on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
The invention discloses Chinese medicinal foot bath powder as well as a processing method and a using method thereof. The foot bath powder comprises safflower, Sichuan lovage rhizome, medicinal cyathula root, common clubmoss herb, suberect spatholobus stem, angelica root, belvedere fruit, pubescent angelica root and paniculate swallowwort root. The processing method of the foot bath powder comprises the following steps of: mixing and preliminarily crushing the components, and finally performing superfine crushing. The using method of the foot bath powder comprises the following steps of: dissolving the foot bath powder into hot water, fuming double feed above a foot basin, regulating the water temperature, and soaking the double feet into the foot basin. The Chinese medicinal foot bath powder prepared by adopting a pure Chinese medicinal formula has the effects of relieving fatigue, relaxing muscles, stimulating blood circulation, expelling wind, removing dampness, preventing cold, sterilizing, relieving itching, removing beriberi and the like. The processing method for the Chinese medicinal foot bath powder is simple and easy, and is simple and convenient to operate, and the medicinal effect of each component in the foot bath powder can be fully exerted by the using the method for the Chinese medicinal foot bath powder.
The adiponectin (APN) levels in obesity are negatively correlated with chronic subclinical inflammation markers. The hypertrophic adipocytes cause obesity-linked insulin resistance and metabolic syndrome. Furthermore, macrophage polarization is a key determinant regulating adiponectin receptor (AdipoR1/R2) expression and differential adiponectin-mediated macrophage inflammatory responses in obese individuals. In addition to decrease in adiponectin concentrations, the decline in AdipoR1/R2 messenger ribonucleic acid (mRNA) expression leads to a decrement in adiponectin binding to cell membrane, and this turns into attenuation in the adiponectin effects. This is defined as APN resistance, and it is linked with insulin resistance in high-fat diet-fed subjects. The insulin-resistant group has a significantly higher leptin-to-APN ratio. The leptin-to-APN ratio is more than twofold higher in obese individuals. An increase in expression of AdipoRs restores insulin sensitivity and β-oxidation of fatty acids via triggering intracellular signal cascades. The ratio of high molecular weight to total APN is defined as the APN sensitivity index (ASI). This index is correlated to insulin sensitivity. Homeostasis model of assessment (HOMA)-APN and HOMA-estimated insulin resistance (HOMA-IR) are the most suitable methods to estimate the metabolic risk in metabolic syndrome. While morbidly obese patients display a significantly higher plasma leptin and soluble (s)E-selectin concentrations, leptin-to-APN ratio, there is a significant negative correlation between leptin-to-APN ratio and sP-selectin in obese patients. When comparing the metabolic dysregulated obese group with the metabolically healthy obese group, postprandial triglyceride clearance, insulin resistance, and leptin resistance are significantly delayed following the oral fat tolerance test in the first group. A neuropeptide, Spexin (SPX), is positively correlated with the quantitative insulin sensitivity check index (QUICKI) and APN. APN resistance together with insulin resistance forms a vicious cycle. Despite normal or high APN levels, an impaired post-receptor signaling due to adaptor protein-containing pleckstrin homology domain, phosphotyrosine-binding domain, and leucine zipper motif 1 (APPL1)/APPL2 may alter APN efficiency and activity. However, APPL2 blocks adiponectin signaling through AdipoR1 and AdipoR2 because of the competitive inhibition of APPL1. APPL1, the intracellular binding partner of AdipoRs, is also an important mediator of adiponectin-dependent insulin sensitization. The elevated adiponectin levels with adiponectin resistance are compensatory responses in the condition of an unusual discordance between insulin resistance and APN unresponsiveness. Hypothalamic recombinant adeno-associated virus (rAAV)-leptin (Lep) gene therapy reduces serum APN levels, and it is a more efficient strategy for long-term weight maintenance.
This review presents the latest insights on robot-assisted kidney autotransplantation (RAKAT). RAKAT is a minimally invasive surgical procedure and represents a promising alternative to conventional laparoscopic nephrectomy followed by open kidney transplantation for the treatment of various complex urological and vascular conditions. RAKAT can be performed either extracorporeally or intracorporeally. Additionally, a single-port approach can be performed through one small incision without the need to reposition the patient. Of 86 patients undergoing RAKAT, 8 (9.3%) developed postoperative > Grade 2 Clavien-Dindo (CD) complications. Although the feasibility of RAKAT was established in 2014, the long-term efficacy and safety along with outcomes of this surgical approach are still being evaluated, and additional studies are needed. With improvements in the technology of RAKAT and as surgeons gain more experience, RAKAT should become increasingly used and further refined, thereby leading to improved surgical outcomes and improved patients' quality of life.
A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
The present invention relates to tools and methods for producing antibodies that specifically bind to chemokine receptors (e.g., CC or CXC chemokines). The present invention provides isolated sulfated polypeptides and conjugates thereof, which may be used, for example, as antigens or for off-target panning to facilitate the production of anti-human, anti-cynomolgus monkey and/or anti-mouse chemokine receptor antibodies, for example, for the production of antibodies with fully human CDRs and/or other advantageous properties for therapeutic use. The invention also relates to antibodies and conjugates thereof obtainable by applying the above tools and methods. Antibodies that specifically bind to human, cynomolgus monkey and/or murine CCR8 are provided that have advantageous properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, hypointernalizing (including non-internalizing) antibodies, and antibodies effective in inducing ADCC and/or ADCP in Treg cells. Also provided are medical uses and/or methods of treatment of the antibodies or conjugates of the invention, comprising administering these antibodies, alone or in combination, to a patient or subject. Biomarkers, stratification methods, and diagnostic methods are ultimately provided to predict or assess responsiveness to anti-CCR 8 antibody monotherapy or combination therapies. The invention also provides tools and methods for producing the antibodies, pharmaceutical compositions, diagnostic uses of the antibodies, and kits with instructions for use.
Pituitary tumors, including prolactinomas, present significant clinical challenges that require a deeper understanding of their molecular roots for improved diagnostics and therapies. Here, we investigate the role of the phosphatase and tensin homolog (PTEN)/phosphoinositide 3-kinase (PI3K) pathway in pituitary tumorigenesis using a mouse model. Conditional knockout of Pten in all pituitary cell lineages resulted in prolactinoma formation exclusively in female mice, demonstrating the critical role of PTEN in pituitary homeostasis. While Pten inactivation induced Akt activation in all pituitary cells, only prolactin-producing cells exhibited tumorigenic changes, suggesting specific cell-type effects. Histological and molecular analyses of prolactinomas revealed similarities with human pituitary tumors, such as decreased vascularization and cell adhesion proteins and increased accumulation of cell cycle proteins. Notably, prolactinomas displayed diminished levels of phosphorylated extracellular signal-regulated kinase (ERK), implicating downregulation of ERK in tumorigenesis. Finally, we analyzed PTEN/PI3K activation in a collection of human pituitary tumors. Overall, our study delineates the intricate interplay between the PTEN and ERK signaling pathways, providing insights into sex-specific mechanisms of pituitary tumorigenesis and potential therapeutic strategies for prolactinomas.
The Hydroxycarboxylic acid receptor 2 (HCA2), also known as the niacin receptor or GPR109A, is a prototypical GPCR that plays a central role in the inhibition of lipolytic and atherogenic activities. Its activation also results in vasodilation that is linked to the side-effect of flushing associated with dyslipidemia drugs such as niacin. GPR109A continues to be a target for developing potential therapeutics in dyslipidemia with minimized flushing response. Here, we present cryo-EM structures of the GPR109A in complex with dyslipidemia drugs, niacin or acipimox, non-flushing agonists, MK6892 or GSK256073, and recently approved psoriasis drug, monomethyl fumarate (MMF). These structures elucidate the binding mechanism of agonists, molecular basis of receptor activation, and insights into biased signaling elicited by some of the agonists. The structural framework also allows us to engineer receptor mutants that exhibit G-protein signaling bias, and therefore, our study may help in structure-guided drug discovery efforts targeting this receptor.
BACKGROUND: Scar contracture bands after burns are frequent problems that cause discomfort and physical limitation. This study investigates the efficacy of a minimally invasive contracture band release technique (MICBR) inspired by closed platysmotomy.
METHODS: Patients with burn scars treated with MICBR in our center were included retrospectively. Our routine scar and contracture treatments (non-invasive and invasive) were utilized prior to undergoing MICBR. Range of motion (ROM) and Vancouver Scar Scale was measured before and after the procedure when feasible.
RESULTS: Forty-five patients were included, with 97 total contracture sites treated all over the body. An average of 1.6 sites were treated per patient, with a maximum of six. Patients age was 6-68 years; total burn surface area ranged from 0.5% to 85%. 24% were performed under local anesthesia. 84% were in originally skin grafted areas. We found significant improvements in ROM and VSS. 84% of patients surveyed were "satisfied" or "very satisfied". 95% reported improved mobility. No significant adverse events occurred.
CONCLUSION: This MICBR technique is a versatile, safe, and well-tolerated adjunct procedure that can help patients regain mobility after a burn injury.
A Brain-Computer Interface (BCI) based rehabilitation system and method is described in which an auditory or visual stimulus is provided to a user instructing them to imagine performing a physical action with a body part such as a hand during a trial period. A BCI processes the electroencephalography (EEG) signals to perform feature extraction and then feature translation (classification) to determine if the user intended to perform the action. If the intension was detected the body part is incrementally moved to provide proprioceptive feedback to the user. The feedback process is repeated at a Feedback Update Interval (FUI) of 100 ms or less. Preferably a reaction time test is used to determine the optimal FUI for an individual where shorter FUIs used for shorter reaction times. In one embodiment, if the user has slow reaction times, the FUI is initially between 100 ms and 1000 ms and gradually decreased over a series of sessions until the FUI is less than 100 ms.
Sickle cell disease is an inherited blood disorder that affects approximately 100,000 people in the United States. People living with sickle cell disease have numerous complications that cause significant morbidity and mortality such as painful episodes of vasoocclusion, acute chest syndrome, stroke, end organ damage, and early death. Unfortunately, their lifespan remains markedly shorter than the general population and this had not dramatically changed in the last 2 decades. Adults, are now not dying primarily from infections and sickle cell disease related complications, but cardiopulmonary disease is a leading cause of death. The etiology of cardiopulmonary disease in sickle cell disease is unclear but studies suggest that microvascular hypoxia, inflammation and endothelial dysfunction play a major role in the pathogenesis. In the general population, exercise reduces cardiovascular complications, pulmonary exacerbations, and decreases cardiovascular death. However, exercise used as primary or secondary prevention in sickle cell disease for cardiopulmonary disease has not been explored. Evidence shows that exercise in sickle cell disease can decrease oxidative stress, lower blood viscosity, and increase nitric oxide levels in both human and mouse models, but there remains some concern that high-intensity training in sickle cell disease may trigger vaso-occlusive crisis and adverse outcomes. However, multiple recent studies show that moderate intensity exercise can be safely performed in adults with sickle cell disease. Currently, providers lack evidence-based knowledge to inform the quantity and quality of regular exercise training that is safe but also improves cardiovascular outcomes in sickle cell disease. In addition, data does not exist on the feasibility and adherence of home-based training regimens in adults with sickle cell disease. Only one study has explored the feasibility and adherence in children. This study will be a qualitative assessment of potential interventions of exercises in adults with sickle cell anemia, only including the more severe genotypes of sickle cell disease.
The invention discloses a norepinephrine chemiluminescent probe and a preparation method and application thereof. The probe of the invention selects 2-chloro-3-hydroxybenzaldehyde and p-methyl thiophenol as main raw materials to construct a near infrared chemiluminescent probe CL-NE for detecting norepinephrine. The probe has good selectivity, high sensitivity and long chemiluminescent duration. According to the research of the invention, the chemiluminescent intensity is enhanced along with the increase of the norepinephrine, and the probe is proved to be suitable for quantitatively detecting the norepinephrine. It realizes the norepinephrine detection of the cell physiological level and the mouse brain tissue level. More importantly, the probe realizes detection of norepinephrine in brain of a Parkinson model mouse. The probe can be an effective tool for monitoring norepinephrine in Alzheimer's disease, parkinson's disease and other related nervous system diseases and disease diagnosis.
Used of a 18.5Fr bipolar resector for hysteroscopic myomectomy. Cervical dilatation would be performed until Hegar bougie number 7 and then a classic hysteroscopic resection will be performed with a 18.5Fr bipolar resector.
The present invention belongs to the field of medicinal preparations. The present invention relates to a 10-hydoxy camptothecin self micro emulsion composition and a preparation method thereof. Self micro emulsion of the present invention is prepared from an oil phase, a surface active agent and cosurfactant. The self micro emulsion can be directly used; moisture which has the noncritical ratio can also be added to the self micro emulsion, and the self micro emulsion is diluted into stable products which have the arbitrary concentration to be used. After the self micro emulsion of 10-hydoxy camptothecin arrives at a human body in an injection mode or an oral administration mode, when the self micro emulsion encounters body fluid, the present invention can lead the self micro emulsion to be automatically formed into micro emulsion which has the nanometer scale particle diameter. The dissolvability of the medicine can be obviously enhanced, the stability of the medicine is increased, and the biological availability of the medicine is enhanced.